Shape Therapeutics’ next-generation gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. This is done by redirecting the human cellular machinery already present in our cells, thereby bypassing risks of in vivo immunogenicity and permanent off-target damages commonly associated with CRISPR-based technologies.

Administration

Software Engineering

Legal

Operations

Quality Assurance

United States

Seattle, WA, USA

Shape Therapeutics

Alix Ventures

BIOS Community

Join TechBio Companies Driving Patient Impact